Ascletis Files to Start Trials of Interferon-Free Hepatitis C Treatment

Ascletis, a Hangzhou-US clinical stage pharma, reported that China and Taiwan have accepted a clinical trial application to test its dual-drug, interferon-free regimen for chronic hepatitis C. Ascletis is the first China company to achieve this milestone. "There are no direct-acting antiviral agents (DAAs) approved in China, and no China companies have filed to start clinical trials of more than one DAA in China," Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis, told ChinaBio® Today in a telephone interview. "We are very competitive against both domestic and multinational pharmas." More details.... Share this with colleagues: // //